Journal issues > Issue 5, September 2024 > Highlights in acute lymphoblastic leukaemia

Highlights in acute lymphoblastic leukaemia

SUMMARY

The EHA 2024 congress was not only the opportunity to present updates on CAR-T cell therapy in the field of acute lymphoblastic leukaemia (ALL), but was also the occasion to present clinical updates on the use of blinatumomab in first-line treatment and important clinical studies for patients with Philadelphia-positive ALL. Below, we will discuss some of the key take-home messages from these sessions.

(BELG J HEMATOL 2024;15(5):201–4)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top